Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Ltd (GLENMARK) last reported results for the quarter ended Jun 2026, with sales of ₹4,018 crore and net profit of ₹483 crore. The stock last traded at ₹2,302, a market capitalisation of ₹64,961 crore, on a P/E of 20.8. Over the past 52 weeks the stock has ranged between ₹1,793 and ₹2,538. Figures are as of 6 Oct 2026 and are not real time.
Glenmark Pharmaceuticals Ltd share price and key metrics
- Current price
- ₹2,302
- Market cap
- ₹64,961 cr
- Stock P/E
- 20.8
- Book value
- ₹372
- ROE
- 23.6%
- ROCE
- 39.8%
- Dividend yield
- 0.22%
- 52w high / low
- 2538/1793
Metrics as of 6 Oct 2026. Not real time.
Track Glenmark Pharmaceuticals Ltd
Cruxal reads every Glenmark Pharmaceuticals Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Glenmark Pharmaceuticals Ltd growth and returns
- 10 Years
- 8%
- 5 Years
- 9%
- 3 Years
- 14%
- TTM
- 33%
- 10 Years
- 12%
- 5 Years
- 19%
- 3 Years
- 61%
- TTM
- 134%
- 10 Years
- 9%
- 5 Years
- 35%
- 3 Years
- 42%
- 1 Year
- 16%
- 10 Years
- 7%
- 5 Years
- 2%
- 3 Years
- -3%
- Last Year
- 24%
Glenmark Pharmaceuticals Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹4,018 cr, up 23.1% from ₹3,264 cr a year earlier. Net profit was ₹483 cr, up 927.7% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 3,434 | 3,388 | 3,256 | 3,264 | 6,047 | 3,901 | 3,771 | 4,018 |
| Expenses | 2,832 | 2,787 | 2,695 | 2,684 | 3,687 | 3,031 | 3,008 | 3,214 |
| Operating profit | 602 | 600 | 561 | 581 | 2,360 | 870 | 763 | 805 |
| OPM % | 18% | 18% | 17% | 18% | 39% | 22% | 20% | 20% |
| Other income | 39 | 31 | -361 | -297 | -1,184 | -140 | -184 | 66 |
| Interest | 48 | 52 | 67 | 58 | 66 | 41 | 43 | 54 |
| Depreciation | 120 | 123 | 125 | 130 | 141 | 154 | 148 | 173 |
| Profit before tax | 473 | 456 | 8 | 96 | 967 | 534 | 388 | 643 |
| Tax % | 25% | 24% | 45% | 51% | 37% | 24% | 22% | 25% |
| Net profit | 354 | 348 | 4 | 47 | 610 | 403 | 301 | 483 |
| EPS (₹) | 12.55 | 12.33 | 0.16 | 1.66 | 21.63 | 14.29 | 10.68 | 17.11 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Glenmark Pharmaceuticals Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 9,079 | 9,074 | 9,865 | 10,641 | 10,944 | 12,305 | 11,583 | 11,813 | 13,322 | 16,983 | 17,737 |
| Operating profit | 2,037 | 1,617 | 1,586 | 1,699 | 2,084 | 2,327 | 1,635 | 1,195 | 2,351 | 4,572 | 4,797 |
| OPM % | 22% | 18% | 16% | 16% | 19% | 19% | 14% | 10% | 18% | 27% | 27% |
| Net profit | 1,109 | 804 | 925 | 776 | 970 | 994 | 377 | -1,434 | 1,047 | 1,362 | 1,798 |
| EPS (₹) | 39.29 | 28.49 | 32.78 | 27.50 | 34.38 | 33.37 | 10.53 | -53.22 | 37.11 | 48.26 | 63.71 |
TTM is the trailing twelve months to the most recent quarter.
Glenmark Pharmaceuticals Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 |
| Reserves | 4,464 | 5,135 | 5,577 | 6,042 | 7,036 | 9,058 | 9,446 | 7,820 | 8,821 | 10,484 |
| Borrowings | 4,724 | 4,639 | 4,449 | 4,869 | 4,986 | 3,962 | 4,608 | 1,231 | 2,473 | 594 |
| Other liabilities | 2,548 | 2,793 | 3,235 | 3,729 | 3,524 | 4,003 | 5,289 | 5,279 | 4,669 | 8,801 |
| Total liabilities | 11,764 | 12,595 | 13,289 | 14,668 | 15,575 | 17,052 | 19,371 | 14,358 | 15,991 | 19,907 |
| Fixed assets | 2,755 | 3,030 | 3,670 | 5,029 | 5,129 | 5,887 | 5,422 | 4,210 | 4,487 | 5,915 |
| CWIP | 708 | 1,122 | 1,399 | 1,222 | 1,382 | 1,010 | 1,190 | 662 | 835 | 909 |
| Investments | 16 | 15 | 30 | 25 | 25 | 50 | 45 | 790 | 56 | 42 |
| Other assets | 8,285 | 8,429 | 8,190 | 8,393 | 9,040 | 10,105 | 12,715 | 8,697 | 10,613 | 13,041 |
| Total assets | 11,764 | 12,595 | 13,289 | 14,668 | 15,575 | 17,052 | 19,371 | 14,358 | 15,991 | 19,907 |
As reported by the company. Total assets equal total liabilities by construction.
Glenmark Pharmaceuticals Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 657 | 1,648 | 1,324 | 1,392 | 1,131 | 1,109 | 625 | -265 | -828 | 3,445 |
| Cash from investing | -1,001 | -1,003 | -883 | -774 | -662 | -316 | -515 | 4,387 | 58 | -1,237 |
| Cash from financing | 543 | -468 | -739 | -445 | -442 | -520 | -77 | -3,906 | 787 | -2,709 |
| Net cash flow | 199 | 177 | -297 | 174 | 28 | 272 | 32 | 215 | 17 | -501 |
| Free cash flow | -76 | 625 | 712 | 616 | 456 | 320 | 75 | -1,162 | -1,576 | 2,090 |
| CFO / operating profit | 67% | 124% | 111% | 109% | 79% | 72% | 77% | 65% | -6% | 92% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Glenmark Pharmaceuticals Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 21% | 15% | 15% | 14% | 15% | 16% | 10% | 12% | 19% | 40% |
| Debtor days | 97 | 94 | 81 | 83 | 86 | 92 | 115 | 57 | 92 | 107 |
| Inventory days | 299 | 244 | 244 | 211 | 230 | 208 | 203 | 208 | 254 | 264 |
| Days payable | 243 | 225 | 241 | 210 | 226 | 190 | 172 | 210 | 256 | 288 |
| Cash conversion cycle | 152 | 113 | 85 | 84 | 90 | 110 | 147 | 56 | 90 | 83 |
| Working capital days | 125 | 99 | 64 | 54 | 67 | 65 | 141 | -2 | 44 | 81 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Glenmark Pharmaceuticals Ltd shareholding pattern
Promoters held 46.65% at Jun 2026, broadly unchanged since Jun 2025. FIIs 20.89% and DIIs 18.60%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 46.65% | 46.65% | 46.65% | 46.64% | 46.64% | 46.65% | 46.65% | 46.65% |
| FIIs | 23.05% | 23.51% | 23.15% | 20.62% | 20.73% | 19.20% | 20.35% | 20.89% |
| DIIs | 13.21% | 13.85% | 14.60% | 17.64% | 18.61% | 20.09% | 19.28% | 18.60% |
| Government | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% |
| Public | 17.06% | 15.96% | 15.56% | 15.05% | 13.97% | 14.02% | 13.70% | 13.81% |
| No. of shareholders | 1,93,949 | 1,95,059 | 1,92,724 | 1,90,210 | 1,98,789 | 2,01,584 | 1,96,105 | 2,11,418 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Cruxal coverage of Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Ltd corporate filings
- Glenmark Therapeutics Inc. USA launches Pump Packs for Adapalene Gel USP, 0.1% (OTC)Company Updatelow impact
Cruxal's analysis: Glenmark Pharmaceuticals announced the launch of Pump Packs for its OTC product Adapalene…
Read the full analysis - Intimation for closure of trading window for second quarter of FY 2026-27Insider Trading / SASTlow impact
- Glenmark Pharmaceuticals receives VAI classification for Goa facility from U.S. FDACompany Updatemedium impact
Cruxal's analysis: Glenmark Pharmaceuticals has received an Establishment Inspection Report (EIR) from the…
Read the full analysis - Glenmark Pharmaceuticals schedules analyst and institutional investor meetingsCompany Updatelow impact
Cruxal's analysis: Glenmark Pharmaceuticals has issued a routine disclosure regarding upcoming meetings with…
Read the full analysis - Glenmark Pharmaceuticals concludes 48th AGM; shareholders approve INR 2.50 per share dividend for FY 2025-26AGM/EGMlow impact
Cruxal's analysis: Glenmark Pharmaceuticals Limited has successfully concluded its 48th Annual General…
Read the full analysis - Glenmark Pharmaceuticals launches RYALTRIS in Brazil to expand respiratory portfolioCompany Updatelow impact
Cruxal's analysis: Glenmark Pharmaceuticals has announced the commercial launch of RYALTRIS, a fixed-dose…
Read the full analysis - India Ratings upgrades Glenmark Pharmaceuticals' long-term bank loan rating to IND AA+/StableCompany Updatehigh impact
Cruxal's analysis: Glenmark Pharmaceuticals Limited has received a credit rating upgrade from India Ratings…
Read the full analysis - Glenmark Pharmaceuticals Inc. USA launches Calcium Gluconate Injection USP in multiple dosage formatsCompany Updatelow impact
Cruxal's analysis: Glenmark Pharmaceuticals Inc., USA has launched Calcium Gluconate Injection USP in three…
Read the full analysis - Glenmark Pharmaceuticals receives U.S. FDA approval for Fluticasone Propionate Nasal SprayCompany Updatemedium impact
Cruxal's analysis: Glenmark Pharmaceuticals has received final approval from the U.S. Food and Drug…
Read the full analysis - Glenmark Pharmaceuticals announces 48th Annual General Meeting scheduled for September 11, 2026Company Updatelow impact
Cruxal's analysis: Glenmark Pharmaceuticals Limited has issued a public notice regarding its 48th Annual…
Read the full analysis - Glenmark Pharmaceuticals issues notice to shareholders for Annual Report accessCompany Updatelow impact
Cruxal's analysis: Glenmark Pharmaceuticals has issued a communication to shareholders who have not…
Read the full analysis - Glenmark Pharmaceuticals releases Business Responsibility and Sustainability Report (BRSR) for FY 2025-26Otherslow impact
Cruxal's analysis: Glenmark Pharmaceuticals has filed its Business Responsibility and Sustainability Report…
Read the full analysis - Glenmark Pharmaceuticals schedules 48th Annual General MeetingOtherslow impact
Cruxal's analysis: Glenmark Pharmaceuticals has issued the notice for its 48th Annual General Meeting, which…
Read the full analysis - Glenmark Pharmaceuticals announces 48th AGM for September 11, 2026, with dividend declaration of INR 2.50 per shareAGM/EGMlow impact
Cruxal's analysis: Glenmark Pharmaceuticals Limited has scheduled its 48th Annual General Meeting for…
Read the full analysis - Glenmark Pharmaceuticals files settlement agreement under SEBI Regulation 30Company Updatelow impact
Cruxal's analysis: Glenmark Pharmaceuticals has submitted a disclosure regarding a settlement agreement in…
Read the full analysis - Glenmark Pharmaceuticals Ltd announces allotment of shares under ESOP 2016Company Updatelow impact
Cruxal's analysis: Glenmark Pharmaceuticals has completed an allotment of shares pursuant to the exercise of…
Read the full analysis - Glenmark Pharmaceuticals schedules analyst and institutional investor meetingsCompany Updatelow impact
Cruxal's analysis: Glenmark Pharmaceuticals has issued an intimation regarding upcoming meetings with…
Read the full analysis - Glenmark Pharmaceuticals schedules 48th Annual General Meeting for September 11, 2026Company Updatelow impact
Cruxal's analysis: Glenmark Pharmaceuticals Limited has announced its 48th Annual General Meeting (AGM) to…
Read the full analysis - Glenmark Pharmaceuticals Limited releases transcript of Q1 FY27 earnings callCompany Updatelow impact
Cruxal's analysis: Glenmark Pharmaceuticals Limited has filed the transcript of its earnings call held on…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.